QT Interval Prolongation with One or More QT-Prolonging Agents Used as Part of a Multidrug Regimen for Rifampicin-Resistant Tuberculosis Treatment: Findings from Two Pediatric Studies-Reference-Cited by-同舟云学术

QT Interval Prolongation with One or More QT-Prolonging Agents Used as Part of a Multidrug Regimen for Rifampicin-Resistant Tuberculosis Treatment: Findings from Two Pediatric Studies

Published:2023-07-18 Issue:7 Volume:67 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Ali Ali Mohamed¹²^ORCID,Radtke Kendra K.¹^ORCID,Hesseling Anneke C.³,Winckler Jana³,Schaaf H. Simon³,Draper Heather R.³,Solans Belén P.¹^ORCID,van der Laan Louvina³^ORCID,Hughes Jennifer³,Fourie Barend³,Nielsen James⁴,Garcia-Prats Anthony J.³⁵^ORCID,Savic Rada M.¹^ORCID

Affiliation:

1. Department of Bioengineering and Therapeutic Sciences, University of California San Francisco, San Francisco, California, USA

2. Bagamoyo Research and Training Center, Ifakara Health Institute, Bagamoyo, Tanzania

3. Desmond Tutu TB Centre, Department of Paediatrics and Child Health, Faculty of Medicine and Health Sciences, Stellenbosch University, Stellenbosch, South Africa

4. Department of Pediatrics, New York University School of Medicine, New York, New York, USA

5. Department of Pediatrics, University of Wisconsin-Madison School of Medicine and Public Health, Madison, Wisconsin, USA

Abstract

Rifampicin-resistant tuberculosis (RR-TB) involves treatment with many drugs that can prolong the QT interval; this risk may increase when multiple QT-prolonging drugs are used together. We assessed QT interval prolongation in children with RR-TB receiving one or more QT-prolonging drugs.

Funder

Bill and Melinda Gates Foundation

HHS | NIH | Eunice Kennedy Shriver National Institute of Child Health and Human Development

HHS | NIH | National Institute of Allergy and Infectious Diseases

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/aac.01448-22

Reference53 articles.

1. World Health Organization. 2021. Global tuberculosis report 2021. World Health Organization, Geneva, Switzerland.

2. Ongoing challenges to understanding multidrug- and rifampicin-resistant tuberculosis in children versus adults

3. Incidence of multidrug-resistant tuberculosis disease in children: systematic review and global estimates

4. Global burden of drug-resistant tuberculosis in children: a mathematical modelling study

5. World Health Organization. 2020. WHO consolidated guidelines on tuberculosis treatment. Module 4: treatment - drug-resistant tuberculosis treatment. World Health Organization, Geneva, Switzerland.

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pharmacokinetics and cardiac safety of clofazimine in children with rifampicin-resistant tuberculosis;Antimicrobial Agents and Chemotherapy;2024-01-10